Profund Advisors LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 48.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,814 shares of the biopharmaceutical company’s stock after acquiring an additional 24,569 shares during the period. Profund Advisors LLC’s holdings in TG Therapeutics were worth $2,230,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Amalgamated Bank grew its position in TG Therapeutics by 1.1% in the third quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,418,000 after acquiring an additional 424 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 441 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of TG Therapeutics by 21.0% during the third quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 467 shares during the period. Bessemer Group Inc. boosted its position in shares of TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 486 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of TG Therapeutics by 1.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TGTX. HC Wainwright boosted their price target on TG Therapeutics from $60.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. reduced their price objective on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Finally, Zacks Research downgraded TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.50.
TG Therapeutics Price Performance
NASDAQ TGTX opened at $39.43 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The stock’s fifty day moving average price is $34.60 and its 200 day moving average price is $32.00. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $44.65. The company has a market cap of $6.04 billion, a price-to-earnings ratio of 13.79 and a beta of 1.68.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The firm had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. TG Therapeutics’s revenue was up 69.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.03 earnings per share. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 1.31 earnings per share for the current year.
TG Therapeutics Company Profile
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Recommended Stories
- Five stocks we like better than TG Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
